Omeros Corporation (OMER) was Initiated by Maxim Group to “Buy” and the brokerage firm has set the Price Target at $21. Maxim Group advised their investors in a research report released on Jun 3, 2016.
On the company’s financial health, Omeros Corporation reported $-0.54 EPS for the quarter, missing the analyst consensus estimate by $ -0.11 based on the information available during the earnings call on May 10, 2016. Analyst had a consensus of $-0.43. The company had revenue of $7.40 million for the quarter, compared to analysts expectations of $8.56 million. The company’s revenue was up 1797.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.51 EPS.
Omeros Corporation closed down -0.16 points or -1.37% at $11.54 with 2,01,298 shares getting traded on Wednesday. Post opening the session at $11.59, the shares hit an intraday low of $11.01 and an intraday high of $11.7 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
In a different news, on May 18, 2016, Marcia S. Kelbon (VP Patent and General Counsel) sold 15,900 shares at $9.94 per share price. According to the SEC, on Nov 20, 2015, Thomas J. Cable (director) sold 2,000 shares at $13.73 per share price. On Sep 8, 2015, Peter A Md Demopulos (director) purchased 3,962 shares at $12.68 per share price, according to the Form-4 filing with the securities and exchange commission.
Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation coagulopathies and disorders of the central nervous system. Its marketed drug product Omidria is approved in the United States for use during cataract surgery or intraocular lens (IOL) which is replacement surgery to maintain pupil size by preventing intraoperative miosis (pupil constriction) and to reduce postoperative ocular pain. Omidria is derived from its PharmacoSurgery platform which is for patients undergoing ophthalmological arthroscopic urological and other surgical procedures. It also has six clinical-stage development programs in its pipeline which includes a group of preclinical programs as well as two additional platforms: one capable of unlocking new G protein-coupled receptor drug targets and the other used to generate antibodies.